MAP Pharmaceuticals (MAPP -1.2%) intends to refile its new-drug application for its Levadex...

|About: MAP Pharmaceuticals, Inc. (MAPP)|By:, SA News Editor

MAP Pharmaceuticals (MAPP -1.2%) intends to refile its new-drug application for its Levadex migraine treatment later this year after meeting with the FDA, which had expressed concerns about manufacturing problems. MAP believes these problems have been resolved and it won't need to carry out new studies. (PR)